Regeneron recognizes new combos to boost I-O drug Libtayo's cancer response
PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of tumors. However, many people either do not respond to these checkpoint inhibitors, or they eventually develop resistance to them.
The scientists at Regeneron were searching for ways to enhance responses to PD-1 inhibitors, so they turned to bispecific antibodies that link the T cells of the immune system and tumour cells by binding to molecules present on cell surfaces.
Regeneron showed that adding bispecific antibodies aiming a T cell protein called CD28 to its Sanofi-...
